Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia

Raffaele Palmieri, Francesco Buccisano, Luca Maurillo, Maria I. Del Principe, Giovangiacinto Paterno, Adriano Venditti, Giovanni Martinelli, Claudio Cerchione

Research output: Contribution to journalReview articlepeer-review


Baseline cytogenetic/genetic features have been widely recognized to play a critical prognostic role in acute myeloid leukemia (AML) and have proven useful in designing risk-adapted treatment strategies. Nevertheless, to improve further the outcome of aML patients we are still in need of accurate methods to explore the quality of response and to adequately discriminate patients who are likely to relapse over time from those who are in deep and stable remission. in this view, is it well established that measurement of leukemic cells surviving chemotherapy (called measurable residual disease, MRD) during the course of treatment may be a reliable biomarker in predicting relapse. Detection of MRD relies on highly sensitive techniques, such as quantitative polymerase chain reaction and multiparametric flow cytometry, which, due to their levels of specificity and sensitivity, are increasingly included in the decision-making process of AML treatment. in the present manuscript, we will review the current techniques of Mrd investigation and their clinical contribution to aML management.

Original languageEnglish
Pages (from-to)386-394
Number of pages9
JournalMinerva Medica
Issue number5
Publication statusPublished - Oct 2020


  • Acute
  • Myeloid
  • Neoplasm
  • Residual; Flow cytometry; Leukemia

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this